Filing Flows › Ensysce Biosciences (ENSC) › Q2 2026
Ensysce Biosciences (ENSC) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Ensysce Biosciences (ENSC) reported revenue of $1.2M for the second quarter 2026 (Q2 2026), -15% from a year earlier and +21% from the quarter before. Operating margin was -221.3%, net loss $2.6M (220.8% of revenue).
Ensysce Biosciences, Q2 2026: revenue $1.2M (-15% year over year), operating margin -221.3%, net loss $2.6M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2M | +21% | -15% |
| Operating profit | −$2.6M | — | — |
| Net earnings | −$2.6M | — | — |
| Operating cash flow | −$2.0M | — | — |
What changed
Revenue was $1.2M in Q2 2026, down 15% year over year and up 21% from the previous quarter.
Operating costs exceeded revenue by $2.6M, an operating margin of -221.3%. Total costs grew 20% against a revenue fall of 15%. The fastest-growing cost line was Research & development (+29%). The quarter ended with a net loss of $2.6M, narrower than the previous quarter's $3.6M loss.
Operating cash flow was −$2.0M. Non-cash charges added back $7K of depreciation and $2K of share-based compensation. Working capital and other items added $600K.
Questions
What was Ensysce Biosciences' revenue in the second quarter 2026?
Ensysce Biosciences (ENSC) reported revenue of $1.2M for the second quarter 2026 (Q2 2026), -15% from a year earlier and +21% from the quarter before.
Was Ensysce Biosciences profitable in the second quarter 2026?
Operating loss was $2.6M (-221.3% of revenue) and net loss $2.6M.